ATE519496T1 - Therapeutische anwendung von g-csf - Google Patents

Therapeutische anwendung von g-csf

Info

Publication number
ATE519496T1
ATE519496T1 AT03712209T AT03712209T ATE519496T1 AT E519496 T1 ATE519496 T1 AT E519496T1 AT 03712209 T AT03712209 T AT 03712209T AT 03712209 T AT03712209 T AT 03712209T AT E519496 T1 ATE519496 T1 AT E519496T1
Authority
AT
Austria
Prior art keywords
group
csf
rats
days
test
Prior art date
Application number
AT03712209T
Other languages
English (en)
Inventor
Didier Pourquier
Didier Moukoko
Original Assignee
Didier Pourquier
Didier Moukoko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Didier Pourquier, Didier Moukoko filed Critical Didier Pourquier
Application granted granted Critical
Publication of ATE519496T1 publication Critical patent/ATE519496T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03712209T 2002-01-18 2003-01-06 Therapeutische anwendung von g-csf ATE519496T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200610A FR2834898B1 (fr) 2002-01-18 2002-01-18 Nouvelle application therapeutique du g-csf, du gm-csf et du scf
PCT/FR2003/000013 WO2003061685A1 (fr) 2002-01-18 2003-01-06 Application therapeutique du g-csf, du gm-csf et du scf

Publications (1)

Publication Number Publication Date
ATE519496T1 true ATE519496T1 (de) 2011-08-15

Family

ID=27589516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03712209T ATE519496T1 (de) 2002-01-18 2003-01-06 Therapeutische anwendung von g-csf

Country Status (8)

Country Link
EP (2) EP1465653B1 (de)
AT (1) ATE519496T1 (de)
DK (1) DK1465653T3 (de)
ES (2) ES2370290T3 (de)
FR (1) FR2834898B1 (de)
PT (1) PT1465653E (de)
SI (1) SI1465653T1 (de)
WO (1) WO2003061685A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1019082T4 (da) 1997-10-02 2008-10-27 Max Planck Gesellschaft Fremgangsmåde til moduleringen af neovaskularisering og/eller væksten af kollaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2004058287A2 (en) * 2002-12-31 2004-07-15 Axaron Bioscience Ag Methods of treating neurological conditions with hematopoeitic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (de) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passives ersetzen von medien
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
US10039808B2 (en) 2014-10-22 2018-08-07 Michael Chez Method of treating or improving neurological function in a human subject
US9925244B1 (en) 2015-02-17 2018-03-27 Michael Chez Treatment of warts in non-immunosuppressed patients
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (de) 2017-03-31 2020-05-27 Terumo BCT, Inc. Zellexpansion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1019082T4 (da) * 1997-10-02 2008-10-27 Max Planck Gesellschaft Fremgangsmåde til moduleringen af neovaskularisering og/eller væksten af kollaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser
DE10033219A1 (de) * 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
JP3607271B2 (ja) * 2001-03-12 2005-01-05 株式会社Ｇｂｓ研究所 神経損傷の治療薬

Also Published As

Publication number Publication date
EP2277529A1 (de) 2011-01-26
EP2277529B1 (de) 2012-06-06
DK1465653T3 (da) 2011-10-17
SI1465653T1 (sl) 2011-11-30
ES2370290T3 (es) 2011-12-14
ES2389244T3 (es) 2012-10-24
FR2834898B1 (fr) 2005-06-10
PT1465653E (pt) 2011-10-18
EP1465653A1 (de) 2004-10-13
FR2834898A1 (fr) 2003-07-25
WO2003061685A1 (fr) 2003-07-31
EP1465653B1 (de) 2011-08-10

Similar Documents

Publication Publication Date Title
ATE519496T1 (de) Therapeutische anwendung von g-csf
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
EP2548880A3 (de) Zusammensetzungen zur Erhöhung der Telomeraseaktivität
CA2369810A1 (en) Method of treating pain
Kupfer et al. Lithium carbonate and sleep in affective illness
Kochar et al. Electrocardiographic effects of marihuana
EP2640409A1 (de) Synergistische zusammensetzung von pflanzenextrakten zur behandlung von hauterkrankungen mit anomalem zellwachstum
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
EP1621207B1 (de) Kombination von Defibrotide und G-CSF und ihre Verwendung zur Aktivierung hämatopoietischer Vorläuferzellen
CA2563800A1 (en) Spinosyns for wound healing
Silver et al. Interleukin 1β improves survival following cecal ligation and puncture
CA2332935A1 (en) A method for inducing production of growth factors
Austin et al. The beneficial effects of immunostimulation in posttraumatic sepsis
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
EP3217975B1 (de) Verwendung von immunmodulatorisch wirksamen zusammensetzungen zur immuntherapeutischen behandlung von patienten mit myeloischen leukämien
Ku et al. Tinggong (SI 19), a novel acupoint for 2Hz electroacupuncture-induced depressor response
Haan et al. Microenvironmentally dependent effects on murine haemopoiesis by a prolonged interleukin‐1 treatment
Zucali et al. Hematopoietic effects of interleukin-1
CN1589904A (zh) 造血干细胞动员剂制备治疗糖尿病药物的用途
Krehmeier et al. Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM
RU2068266C1 (ru) Способ повышения остроты слуха
Mozaffari et al. In vitro Comparison of Viability of Human Gingival Fibroblast Cells on Collagen Barriers
RU2587638C1 (ru) Способ оптимизации лечения глубоких ожогов
Nishan Role of Placentrex in Dentistry and Oral and Maxillofacial Surgery: A
Gillis Preclinical studies and future directions in the development of new hematologic growth factors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1465653

Country of ref document: EP